SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines

Overview

Journal Vaccines (Basel)

Date 2023 Apr 28

PMID 37112761

Authors

Raju Sunagar

Amit Singh

Sudeep Kumar

Affiliations

Soon will be listed here.

Abstract

The global rollout of COVID-19 vaccines has played a critical role in reducing pandemic spread, disease severity, hospitalizations, and deaths. However, the first-generation vaccines failed to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and transmission, partially due to the limited induction of mucosal immunity, leading to the continuous emergence of variants of concern (VOC) and breakthrough infections. To meet the challenges from VOC, limited durability, and lack of mucosal immune response of first-generation vaccines, novel approaches are being investigated. Herein, we have discussed the current knowledge pertaining to natural and vaccine-induced immunity, and the role of the mucosal immune response in controlling SARS-CoV2 infection. We have also presented the current status of the novel approaches aimed at eliciting both mucosal and systemic immunity. Finally, we have presented a novel adjuvant-free approach to elicit effective mucosal immunity against SARS-CoV-2, which lacks the safety concerns associated with live-attenuated vaccine platforms.

Citing Articles

Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results.

Kutumbetov L, Myrzakhmetova B, Tussipova A, Zhapparova G, Tlenchiyeva T, Bissenbayeva K Vaccines (Basel). 2025; 12(12.

PMID: 39772061 PMC: 11728456. DOI: 10.3390/vaccines12121401.

T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects.

Macchia I, La Sorsa V, Ciervo A, Ruspantini I, Negri D, Borghi M Biomolecules. 2024; 14(10).

PMID: 39456150 PMC: 11505848. DOI: 10.3390/biom14101217.

Mucosal immunity in COVID-19: a comprehensive review.

Alqahtani S Front Immunol. 2024; 15:1433452.

PMID: 39206184 PMC: 11349522. DOI: 10.3389/fimmu.2024.1433452.

SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity.

Tobias J, Steinberger P, Wilkinson J, Klais G, Kundi M, Wiedermann U Vaccines (Basel). 2024; 12(7).

PMID: 39066432 PMC: 11281395. DOI: 10.3390/vaccines12070795.

Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice.

Li J, Hsu K, Howe S, Hoang T, Xia Z, Berzofsky J Front Immunol. 2024; 15:1386243.

PMID: 38835757 PMC: 11148259. DOI: 10.3389/fimmu.2024.1386243.

References

Wallace P, Tsang K, Goldstein J, Correale P, Jarry T, Schlom J . Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J Immunol Methods. 2001; 248(1-2):183-94. DOI: 10.1016/s0022-1759(00)00351-3. View

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

Shrestha A, Sadeyen J, Iqbal M . Enhancing Protective Efficacy of Poultry Vaccines through Targeted Delivery of Antigens to Antigen-Presenting Cells. Vaccines (Basel). 2018; 6(4). PMC: 6313852. DOI: 10.3390/vaccines6040075. View

Suthar A, Wang J, Seffren V, Wiegand R, Griffing S, Zell E . Public health impact of covid-19 vaccines in the US: observational study. BMJ. 2022; 377:e069317. PMC: 9044401. DOI: 10.1136/bmj-2021-069317. View

Wang M, Pan W, Xu Y, Zhang J, Wan J, Jiang H . Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases. J Inflamm Res. 2022; 15:3083-3094. PMC: 9148574. DOI: 10.2147/JIR.S350109. View

Verma S, Weiskopf D, Gupta A, McDonald B, Peters B, Sette A . Cytomegalovirus-Specific CD4 T Cells Are Cytolytic and Mediate Vaccine Protection. J Virol. 2015; 90(2):650-8. PMC: 4702662. DOI: 10.1128/JVI.02123-15. View

Rawool D, Bitsaktsis C, Li Y, Gosselin D, Lin Y, Kurkure N . Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol. 2008; 180(8):5548-57. PMC: 3787710. DOI: 10.4049/jimmunol.180.8.5548. View

Graham J, Authie P, Yu C, Zurawski S, Li X, Marches F . Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes. Vaccine. 2016; 34(41):4857-4865. PMC: 5598757. DOI: 10.1016/j.vaccine.2016.08.071. View

Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S, Sivasubbu S . Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2021; 22(4):473-482. PMC: 8616567. DOI: 10.1016/S1473-3099(21)00680-0. View

10.

Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Maurino V, Baj A . Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine. EBioMedicine. 2023; 88:104435. PMC: 9828819. DOI: 10.1016/j.ebiom.2022.104435. View

11.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

12.

Vikkurthi R, Ansari A, Pai A, Jha S, Sachan S, Pandit S . Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Nat Microbiol. 2022; 7(7):974-985. DOI: 10.1038/s41564-022-01161-5. View

13.

Madhavan M, Ritchie A, Aboagye J, Jenkin D, Provstgaad-Morys S, Tarbet I . Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. EBioMedicine. 2022; 85:104298. PMC: 9550199. DOI: 10.1016/j.ebiom.2022.104298. View

14.

Shishido A, Barnes A, Narayanan S, Chua J . COVID-19 Vaccines-All You Want to Know. Semin Respir Crit Care Med. 2023; 44(1):143-172. DOI: 10.1055/s-0042-1759779. View

15.

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

16.

Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M . Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999; 189(2):371-80. PMC: 2192989. DOI: 10.1084/jem.189.2.371. View

17.

Hanquet G, Valenciano M, Simondon F, Moren A . Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013; 31(48):5634-42. DOI: 10.1016/j.vaccine.2013.07.006. View

18.

Vadrevu K, Ganneru B, Reddy S, Jogdand H, Raju D, Sapkal G . Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. Sci Rep. 2022; 12(1):12038. PMC: 9281359. DOI: 10.1038/s41598-022-16097-3. View

19.

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

20.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View